Home › Funds › FRONTIER CAPITAL MANAGEMENT CO LLC › RARE

FRONTIER CAPITAL MANAGEMENT CO LLC position in RARE

ULTRAGENYX PHARMACEUTICAL IN · Health Care

FRONTIER CAPITAL MANAGEMENT CO LLC reported holding 2,847,936 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$95.1M, representing 0.89% of its reported portfolio and ranking #19 among its reported holdings. FRONTIER CAPITAL MANAGEMENT CO LLC has disclosed RARE holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)2.85M sh
Reported value held$95.09M
Portfolio Weight0.89%
First reportedQ2 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FRONTIER CAPITAL MANAGEMENT CO LLC's RARE position evolved

FRONTIER CAPITAL MANAGEMENT CO LLC first disclosed a stake in RARE in Q2 2025 at 525,464 shares (US$19.1M). The position peaked in Q2 2026 at 2,847,936 shares, worth US$95.1M. Across 5 filings, FRONTIER CAPITAL MANAGEMENT CO LLC increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,847,936 shares valued at US$95.1M — an increase of 656,754 shares quarter over quarter.. Notable position changes include a 103% increase in Q3 2025 (shares fell 24% over the following quarter), a 84% increase in Q4 2025 (shares fell 9% over the following quarter), a 30% increase in Q2 2026 (shares fell 55% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 525.46K $19.11M New
Q3 2025 1.07M $32.16M Add
Q4 2025 1.97M $45.20M Add
Q1 2026 2.19M $45.91M Add
Q2 2026 2.85M $95.09M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RARE and 13F data

RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 26 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), Bellevue Group AG (US$66.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RARE

All RARE fund holders →

FAQ

How long has FRONTIER CAPITAL MANAGEMENT CO LLC held RARE?

FRONTIER CAPITAL MANAGEMENT CO LLC has disclosed RARE holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is FRONTIER CAPITAL MANAGEMENT CO LLC's current position in RARE?

As of Q2 2026, FRONTIER CAPITAL MANAGEMENT CO LLC holds 2.85M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $95.09M, representing 0.89% of its reported portfolio and ranking #19.

Has FRONTIER CAPITAL MANAGEMENT CO LLC been buying or selling RARE?

In the latest 13F filing (Q2 2026), FRONTIER CAPITAL MANAGEMENT CO LLC increased its position in RARE. The position peaked in Q2 2026 at 2.85M shares.

Which other funds hold RARE?

Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, Bellevue Group AG, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.